Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
61 results about "T cell subset" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
T Cell Subset. T-cell subsets are mainly defined by their cytokine secretion and downstream effector function, such as cytoxicity or regulation.
Method for detecting t cell response to specific antigens in whole blood
InactiveUS20010006789A1Unprecedented clarityRoutinely usedBiological testingCell subpopulationsCytokine response
This invention comprises a novel approach to the assessment of antigen-specific T cells that quantitates and characterizes these cells with unprecedented clarity, and importantly, because it is performed in whole blood, is amenable to routine use in the clinical immunology laboratory. The methodology offers an improved flow cytometric intracellular cytokine assay in whole blood that can simultaneously measure multiple T cell subsets expressing multiple cytokines from a single whole blood culture. Evaluation of whole blood antigen specific cytokine responses has the important advantage of assessing T cell activation in the presence of ALL types of MHC autologous antigen presenting cells present in the native sample. It also has the advantage of enabling a culture system (whole blood) which can reflect effects of systemic environments (i.e. drug augmentation or suppression) on T cell responses to specific stimuli including antigen, by either culturing in the presence of such drug or analyzing the blood of a human or animal receiving such drug.
Owner:BECTON DICKINSON & CO +1
Method for automated generation of genetically modified t cells
ActiveUS20170037370A1High transduction efficiencyRobust manufacturingPolypeptide with localisation/targeting motifImmunoglobulin superfamilyProgenitorCentrifugation
The present invention provides a process for generation of genetically modified T cells, T cell subsets and / or T cell progenitors comprising the steps: a) providing a cell sample comprising T cells, T cell subsets and / or T cell progenitors b) preparation of the cell sample by centrifugation c) magnetic separation of the T cells, T cell subsets and / or T cell progenitors d) activation of the enriched T cells, T cell subsets and / or T cell progenitors using modulatory agents e) genetic modification of the T cells, T cell subsets and / or T cell progenitors f) expansion of the genetically modified T cells, T cell subsets and / or T cell progenitors in a cultivation chamber g) washing of the cultured T cells, T cell subsets and / or T cell progenitors characterized in that all steps are performed in a closed and sterile cell culture system.
Owner:MILTENYI BIOTEC B V & CO KG
Activation and Expansion of T Cell Subsets Using Biocompatible Solid Substrates with Tunable Rigidity
InactiveUS20150030619A1Induced differentiationSnake antigen ingredientsCulture processBiological activationSolid substrate
The present invention provides compositions and methods for activation and expansion of T cells using a biocompatible solid substrate with tunable rigidity. Rigidity of a substrate is an important parameter that can be used to control the overall expansion and differentiation of T cells.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA +1
Method for automated generation of genetically modified T cells
ActiveUS10131876B2Robust manufacturingImprove efficiencyPolypeptide with localisation/targeting motifImmunoglobulin superfamilyProgenitorCentrifugation
The present invention provides a process for generation of genetically modified T cells, T cell subsets and / or T cell progenitors comprising the steps: a) providing a cell sample comprising T cells, T cell subsets and / or T cell progenitors b) preparation of the cell sample by centrifugation c) magnetic separation of the T cells, T cell subsets and / or T cell progenitors d) activation of the enriched T cells, T cell subsets and / or T cell progenitors using modulatory agents e) genetic modification of the T cells, T cell subsets and / or T cell progenitors f) expansion of the genetically modified T cells, T cell subsets and / or T cell progenitors in a cultivation chamber g) washing of the cultured T cells, T cell subsets and / or T cell progenitors characterized in that all steps are performed in a closed and sterile cell culture system.
Owner:MILTENYI BIOTEC B V & CO KG
Method for in-vitro amplification of CD8+T cell and cell subset of CD8+T cell
ActiveCN106834228AImprove efficiencyImprove repair functionCell dissociation methodsBlood/immune system cellsTlr agonistsMagnetic bead
The invention establishes a method for in-vitro amplification of a CD8+T cell and a cell subset of the CD8+T cell. By adding a TLR1 / 2 agonist, a TLR2 / 6 agonist and a TLR5 agonist into an in-vitro culture system for conventionally culturing and amplifying the CD8+T cell or conjunctively utilizing the agonists, the amplification efficiency of the CD8+T cell can be remarkably improved; besides, by utilizing a TLC agonist, the functional CD8+T cell subsets which are difficult to amplify under a conventional culture condition are amplified, such as PD-1+CD8+T cells and TEM CD8+T cells; and the CD8+T cells and the functional cell subsets can be rapidly and largely propagated under the common and continuous stimulation of a TLRs agonist, recombinant cell factors IL-2, IL-7 and IL-15, an anti-human CD3 antibody and anti-human CD28 antibody coated magnetic beads.
Owner:SHANGHAI INNOVATIONAL CHANGAN BIOLOGICAL TECH CO LTD
Efficient culture method of CIK (cytokine induced killer) cells
InactiveCN103525763AProliferate fastIncrease the number of cellsBlood/immune system cellsHigh cellPeripheral blood mononuclear cell
The invention aims to provide an efficient culture method of CIK cells. The prepared CIK cell has the characteristics of high multiplication speed, large cell quantity, high cell viability, high killing capacity on cancer cells and the like. The efficient culture method mainly characterized in that a culture flask coated with laminin and fibronectin is used for culturing PBMCs (peripheral blood mononuclear cells), and the cells can be in a half-adherence state by means of the absorption effect of the two kinds of protein, accordingly, the cells can be stimulated by various factors, and the two kinds of protein can promote CIK cell multiplication; and with the adoption of an anti-CD28 monoclonal antibody, the co-stimulation signal of a T cell subset in the CIK cells can be stimulated, and the activation of the CIK cells is promoted. So far, a research report on jointly using laminin, fibronectin and the anti-CD28 monoclonal antibody to prepare the CIK cells is absent. The method for increasing the cell number and improving the killing activity by adding the three factors during preparation of the CIK cells is firstly provided.
Owner:青岛麦迪赛斯生物科技有限公司
T cell subsets in lung cancer and feature genes thereof
ActiveCN109777872AMicrobiological testing/measurementBiological testingRegulatory T cellSingle cell transcriptome
The invention discloses T cell subsets in lung cancer and feature genes thereof. A single-cell transcriptome analysis technology is adopted, and by analyzing a single-cell gene expression profile of infiltrating T cells in the lung cancer tissue, the T cell subsets capable of reflecting body tumor immune states of patients with the lung cancer are separated and characterized, namely the exhaustedCD 8+ T cells or regulatory T cells capable of expressing genes including TNFRSF9, TNFRSF18 and LAYN are separated and characterized. Through research, relations between lung cancer prognosis and thenew feature genes which include TNFRSF9, TNFRSF18 and LAYN and are expressed by the cell subsets are further determined. Therefore, the T cell subsets in lung cancer and the feature genes thereof canbe used for diagnosis and monitoring of lung cancer prognosis and serve as new targets for lung cancer immunotherapy.
Owner:PEKING UNIV
Method for detecting T cell response to specific antigens in whole blood
This invention comprises a novel approach to the assessment of antigen-specific T cells that quantitates and characterizes these cells with unprecedented clarity, and importantly, because it is performed in whole blood, is amenable to routine use in the clinical immunology laboratory. The methodology offers an improved flow cytometric intracellular cytokine assay in whole blood that can simultaneously measure multiple T cell subsets expressing multiple cytokines from a single whole blood culture. Evaluation of whole blood antigen specific cytokine responses has the important advantage of assessing T cell activation in the presence of ALL types of MHC autologous antigen presenting cells present in the native sample. It also has the advantage of enabling a culture system (whole blood) which can reflect effects of systemic environments (i.e. drug augmentation or suppression) on T cell responses to specific stimuli including antigen, by either culturing in the presence of such drug or analyzing the blood of a human or animal receiving such drug.
Owner:BECTON DICKINSON & CO +1
Identification of cd8+ t cells that are cd161hi and/or il18r (ALPHA) hi and have rapid drug efflux capacity
This invention provides, among other things, methods for the identification and isolation of viable putative long-lived antigen-specific memory CD8+ T cell subsets (CMhi and EMhi) with high surface expression of CD161 and / or IL-18Rα and the capacity to rapidly efflux the fluorescent dye Rh123.
Owner:FRED HUTCHINSON CANCER CENT
Application of CD4+CD70+T cell subset in preparing reagent for auxiliary diagnosis of very severe aplastic anemia
ActiveCN109187941AReduce the ratioDisease diagnosisIndividual particle analysisTreatment strategyLaboratory facility
The invention discloses an application of CD4+CD70+T cell subset in preparing reagent for auxiliary diagnosis of very severe aplastic anemia. According to the invention, the inventor finds for the first time that the proportion of CD4+CD70+T cell in the peripheral blood of AA patients is obviously reduced in A patients, especially, is most obvious in VSAA, which can be used as one of related testindices for auxiliary diagnosis of laboratory immunization of VSAA patients, and meanwhile, provides important reference data for selection of treatment strategy for VSAA patients clinically.
Owner:JINAN UNIVERSITY
Biomarkers for predicting response to immunosuppressive therapy
ActiveUS20110091481A1Raise the possibilityMicrobiological testing/measurementAntiviralsCentral Memory T-CellRegimen
The subject invention concerns methods and materials for assessing a patient's likelihood of responsiveness to an immunosuppressive therapy. The subject invention is contemplated for use with patients having an autoimmune disorder. In an exemplified embodiment, the methods of the invention are used for assessing and / or treating a patient with MDS. In one embodiment, a method of the invention comprises analyzing T cells of a patient for dysregulation of CD4+ and / or CD8+ T cell subsets, and determining the patient's likelihood of responsiveness to IST based on the level of dysregulation of the patient's CD4+ and / or CD8+ T cell subsets. In one embodiment, an increased likelihood of patient responsiveness to IST is associated with an increased percentage of CD4+ and / or CD8+ effector memory T cells and / or terminal effector memory T cells, for a patient. The subject invention also concerns methods for treating a patient with an autoimmune disorder, such as MDS. In one embodiment, a method of the invention comprises determining if a patient is likely to respond to IST, wherein said determination is made using a method of the present invention for assessing likelihood of responsiveness to IST; and if the patient is determined to be one likely to respond to IST, administering an effective regimen of IST to the patient.
Owner:UNIV OF SOUTH FLORIDA +1
T-cell subset for cancers and characteristic genes
ActiveCN109081866AMicrobiological testing/measurementBlood/immune system cellsRegulatory T cellSingle cell transcriptome
The invention isolates and characterizes a T-cell subset capable of reflecting body tumor immunity state, namely exhaustible CD8+T-cells to express genes WARS and ACP5 as well as regulatory T-cells toexpress genes STAM and BATF, by analyzing single cell gene expression profiles of T-cells infiltrated in cancer tissues through single cell transcriptome analysis. Further determined by researches are new characteristic genes WARS and ACP5 expressed by the cell subset, and a relationship between the STAM and BATF and prognosis of tumor, as well as application of the genes in tumor prognosis diagnosis and monitoring, and application as new tumor immunotherapy targets.
Owner:PEKING UNIV
Human Crohn disease-simulating murine colitis model, and preparation method and use thereof
The invention discloses a human Crohn disease-simulating murine colitis model, and a preparation method and use thereof. The preparation method comprises the following steps of: (1) establishing the murine colitis model by using trinitro-benzene-sulfonic acid (TNBS) enema; (2) evaluating the establishment of the model by observing general physical signs and observing the activity status of a mouse in real time; (3) after the mouse is killed, detecting clinical indexes, taking the whole colon of the mouse and performing length measurement, disease scoring and histological examination to evaluate the establishment of the murine colitis model; and (4) taking the splenocyte of the mouse and performing T-cell subset distribution checking to determine the change of immunocytes of the model. The invention provides a support for researches on the detection of clinical colitis mediation, and lays a foundation for development and research of effective treatment medicaments.
Owner:INST OF HEMATOLOGY & BLOOD DISEASES HOSPITAL CHINESE ACADEMY OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE
Bladder cancer exhausted T cell subset as well as characteristic genes and application thereof
InactiveCN111748627AMicrobiological testing/measurementBlood/immune system cellsSingle cell transcriptomeCD8
According to the invention, single-cell transcriptome sequencing is carried out on peripheral blood, normal bladder tissues and bladder cancer tissue-derived T cells of an infiltrated bladder cancer patient by utilizing a single-cell transcriptome sequencing analysis technology, a bladder cancer specific T cell subset, namely CD8<+> exhausted T cells, is identified, and characteristic genes, namely genes LUC7L3, IKZF3 and TRGC2, expressed by the CD8<+> exhausted T cells are determined. The characteristic genes can be used for identifying or authenticating CD8<+> exhausted T cells from bladdercancer, can be further used for auxiliary diagnosis, prognosis and immunotherapy of bladder cancer, and provide related detection reagents or kits.
Owner:BEIJING UNIV OF CHEM TECH
Applications of artemisinin compounds in preparing medicines for treating liposarcoma
ActiveCN107569482AOrganic active ingredientsAntineoplastic agentsProgression-free survivalLife quality
The invention relates to the field of medicines, and in particular relates to applications of artemisinin compounds in preparing medicines for treating liposarcoma. The artemisinin compounds are shownin the description. The experiment proves that the compounds can obviously prolong the progression free survival (PFS) of patients and improve the life quality of the patients, while the number of circulating tumor cells (CTCs) is obviously reduced, the ratios of T cell subsets in the peripheral blood are obviously improved, in addition, the safety is high, and the applications are disclosed forthe first time and have the outstanding substantive features. The substances can be applied to preparation of medicines for treating liposarcoma and have good market application prospects.
Owner:北京维恩派科技有限公司
Application of flavonoids compounds in preparation of T lymphocyte subsets regulating drug
InactiveCN105030753AGood treatment effectOrganic active ingredientsSenses disorderDiseaseIntraocular inflammation
The invention provides an application of flavonoids compounds in the preparation of a T lymphocyte subsets regulating drug. The innovative discovery of the invention is that the flavonoids compounds can regulate the proportion of T lymphocyte subsets, so that the effect of immune system is regulated, and the related pathological injury can be cured. Specifically, the proportion of a CD4+IFN-gamma+Th1 cell subset, a CD4+IL-17+Th17 cell subset and a CD4+CD3e+CD62L+ThO cell subset can be lowered, and the proportion of CD4+CD25+Fo8*p3+Treg cell subset is increased. Chrysin can maintain the integrity of the blood-retinal barrier of an EAU mouse, inhibit the macrophage infiltration, and inhibit the intraocular inflammation. At the same time, the expression quantity of retinas STAT1, STAT3 and phosphorylated protein is inhibited. Based on new properties of the flavonoids, the flavonoids can be applied for curing a plurality of diseases with the effect of proportional imbalance of T cell subsets.
Owner:GENERAL HOSPITAL OF TIANJIN MEDICAL UNIV
Scutellaria barbata polysaccharide antitumor mechanism detection research method
InactiveCN105560266APromote activationPromote proliferationOrganic active ingredientsAntineoplastic agentsCell Surface ProteinsTumor therapy
The present invention discloses a scutellaria barbata polysaccharide antitumor mechanism detection research method which comprises the following detecting steps: an in-vivo tumor suppression experiment; ANAE method determination of the total number of T cells in peripheral blood of tumor-bearing mice; flow cytometry determination of T cell subsets and T cell surface protein-CD28 in the peripheral blood of the tumor-bearing mice; and determination of content of IL-2 and IFN-gamma in serum of the peripheral blood of the tumor-bearing mice; the scutellaria barbata polysaccharide in-vivo antitumor and cell immune function influence detection research method discloses a major role of scutellaria barbata polysaccharide in tumor treatment, and meanwhile the study on body cell immune mechanism of plant polysaccharides can be promoted.
Owner:HUAIAN COLLEGE OF INFORMATION TECH
Human Tscm cells and preparation method and application thereof
ActiveCN108148805ARich sourcesUnique creatureMammal material medical ingredientsBlood/immune system cellsCell sorterStimulant
The invention belongs to the field of biological immunology, and particularly relates to human Tscm cells and a preparation method and application thereof. The preparation method comprises the following steps of: (1) acquiring human umbilical cord blood and obtaining human umbilical cord blood mononuclear cells by adopting a density gradient centrifugation method; (2) sorting CD8+CD45RA +CCR7+initial T cell subsets by a flow cell sorter; (3) adding the sorted initial T cell subsets into a medium containing the stimulant CD3 / CD28 beads, the cytokine IL-2 and metformin for culture; and (4) conducting medium change and cytokine IL-2 supplement every 2 days, so that CD8+T cells with a Tscm phenotype can be obtained after 14 days of amplification. By the adoption of the method, a large number of T cells with a memory characteristic and a low differentiation state can be obtained for the treatment of tumors.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
Rapamycin-resistant T cells and therapeutic uses thereof
InactiveUS7718196B2Reduce riskAvoid dilutionOrganic active ingredientsArtificial cell constructsAllo hsctPharmaceutical drug
Methods for generating highly enriched Th1 / Tc1 and Th2 / Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer.
Owner:UNITED STATES OF AMERICA +1
Methods of using ceo2 and tio2 nanoparticles in modulation of the immune system
InactiveUS20150190503A1Good curative effectModulating the immune systemHeavy metal active ingredientsPowder deliveryDc maturationCeo2 nanoparticles
Redox-active NPs are disclosed that can potentiate innate immunity and stimulate distinct adaptive responses, producing distinct T cell subset polarization outcomes. Nanomaterials that can alter the cellular redox environment through ROS modulation can impact human immunology. TiO2 nanoparticles potentiate DC maturation, inducing the secretion of IL-12, p70, and IL-1B, while treatment with CeO2 nanoparticles induces IL-10, a hallmark of suppression. When delivered to T cells, the materials direct distinct TH polarization, where TiO2 stimulates largely a TH1 dominated response, whereas CeO2 stimulates a TH2 bias and TReg differentiation.
Owner:SANOFI PASTEUR VAX DESIGN +1
Methods and compositions for regulating T cell subsets by modulating transcription factor activity
InactiveUS20070009918A1Peptide/protein ingredientsAntibody mimetics/scaffoldsTranscription factor activityAssay
Methods for modulating production of a T helper type 2 (Th2)-associated cytokine, in particular interleukin-4, by modulating the activity of a transcription factor, in particular the proto-oncoprotein c-Maf, that regulates expression of the Th2-associated cytokine gene are disclosed. Methods for modulating development of T helper type 1 (Th1) or T helper type 2 (Th2) subsets in a subject using agents that modulate transcription factor activity are also disclosed. The methods of the invention can further involve use of agents that modulate the activity of additional transcription factors that contribute to the regulation of Th1- or Th2-associated cytokines, such as a Nuclear Factor of Activated T cells (NF-AT) protein and / or an AP-1 family protein. Compositions for modulating Th2-associated cytokine production, recombinant expression vectors and host cells, as well as screening assays to identify agents that modulate c-Maf activity, are also disclosed.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Diagnostic and immunotherapy compositions and methods for disease states mediated by inhibitor-resistant cd8 t-cells
Owner:JOHNSON RAYMOND M
Application of advanced effect T cell subset in preparation of kit for assisting in evaluating condition degree of aplastic anemia
PendingCN111856007AReduce the ratioGeneral immune abnormalitiesDisease diagnosisBiological testingDiseaseImmunity
The invention discloses application of an advanced effect T cell subset in preparation of a kit for assisting in evaluating the disease degree of aplastic anemia. That the ratio of CD4 + CD45RO + CD27-T cells in peripheral blood of an AA patient is significantly reduced is found for the first time; the VSAA and the SAA of the AA patient are obviously lower than those of healthy people; only the proportion of CD4 + CD45RO + CD27-T cells in peripheral blood of VSAA and SAA patients is significantly lower than the characteristic change of NSAA patients, and the characteristic change can be used as one of laboratory immunity related detection index for assisting evaluating the illness severity of AA patients. Meanwhile, important reference data are provided for clinical selection of treatmentstrategies for AA patients with different disease degrees in the future.
Owner:JINAN UNIVERSITY
Cell subset for immunotherapy of primary hepatocellular carcinoma and preparation method thereof
ActiveCN110484504AImprove tumor killing abilityGood effectBlood/immune system cellsCell culture active agentsAbnormal tissue growthCD137
The invention provides a cell subset for immunotherapy of primary hepatocellular carcinoma, namely a CD137 + CD3 + CD8 + CD45RO + T cell subset. The invention also provides a preparation method of theabove cell subset. The method comprises the following steps: firstly labeling a T cell subset in tumor tissues with a specific marker, and then carrying out flow cell sorting on the CD137 + CD3 + CD8+ CD45RO + T cell subset, and carrying out in-vitro expansion culture to obtain the cell subset for immunotherapy of primary hepatocellular carcinoma. The cell subset of the invention has stronger tumor-killing effect, anti-apoptosis capacity and multiplication capacity, and can survive in vivo for a long time. The invention aims to provide effective candidate cell populations for immunotherapy of liver cancer, especially T cell immunotherapy of tumor infiltration, and provide new ideas for treatment of other tumors.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV
Medical usage of russula griseocarnosa polysaccharide in treatment of systemic lupus erythematosus
InactiveCN107050044ATreatment safetyDecreased IL-10, ds-DNA antibodiesOrganic active ingredientsSkeletal disorderRegulatory T cellDna antibody
The invention discloses a medical usage of russula griseocarnosa polysaccharide in treatment of systemic lupus erythematosus. The russula griseocarnosa polysaccharide PRG1-2 has the advantages of adjusting the activity of T cell subset, reducing IL-10, ds-DNA antibody and urine protein, being obviously effective in treatment, safe and reliable. Provided is an application of the russula griseocarnosa polysaccharide PRG1-2 with a wide clinical application prospect in preparation of medicine for treating systemic lupus erythematosus.
Owner:JILIN UNIV
Biomarkers for predicting response to immunosuppressive therapy
InactiveUS9176122B2Microbiological testing/measurementSnake antigen ingredientsDiseaseCentral Memory T-Cell
Owner:UNIV OF SOUTH FLORIDA +1
Regulatory cells that control T cell immunoreactivity
InactiveUS20060110372A1Abnormally increasedOrganic active ingredientsBiocideExperimental methodsRegulatory T cell
[Subject] To provide regulatory T cells that suppress activated CD8+ killer T cells with tissue-damaging or cytotoxic effects. [Solution means] CD8+CD122+ T cell subsets are provided as regulatory T cells that suppress activity of activated CD8+ killer T cells. Administration of these T cell subsets can suppress tissue / cell damages. In addition, it has become possible to explore agents that augment immunosuppressive activity of these T cell subsets by using the experimental method described in the present invention.
Owner:IMMUNOFRONTIER +1
Identifcation of CD8+ T cells that are CD161hi and/or IL18Rαhi and have rapid drug efflux capacity
Owner:FRED HUTCHINSON CANCER CENT
Medicine for treating asthma and kidney qi deficiency, animal model and establishing and using method
The invention discloses a medicine for treating asthma and kidney qi deficiency, an animal model and an establishing and using method. The medicine for treating asthma and kidney qi deficiency is prepared from 12g of prepared rehmannia roots, 12g of pulp of dogwood fruit, 12g of rhizoma dioscoreae, 12g of rhizoma alismatis, 12g of radix sophorae flavescentis, 12g of Japanese metaplexis pericarp, 12g of tree peony bark, 12g of poria cocos, 5g of schisandra chinensis, 8g of agilawood pieces, 15g of inula flowers, 15g of indigo naturalis and clam powder and 15g of raw radix astragalis. In the early period, a kidney qi deficiency and asthma symptom combined rat model is established, and it is observed that kidney tonifying and asthma relieving soup and glucocorticoid can correct Th1 / Th2 unbalance by adjusting expression of transcription factors. Specificity transcription factors, key cell factors and tiny RNA of a T cell subset serve as indexes, an internal mechanism of kidney qi deficiency asthma attacking and Treg / Th balance is proved, and a multi-target-point multi-layered network type regulatory mechanism possibly existing in traditional Chinese medicine for treating asthma is disclosed.
Owner:ZHEJIANG CHINESE MEDICAL UNIVERSITY
Immune toxicity evaluation method for new medicine development
The invention provides immune toxicity evaluation application of human peripheral blood monocytes for new medicine development. The method for new medicine toxicology evaluation through human peripheral blood monocytes comprises the steps of 1, preparing the human peripheral blood monocytes; 2, using control medicine and new medicine to be measured for processing the human peripheral blood monocytes obtained in the step 1; 3, using a CCK-8 method and a CFSE dyeing method for detecting proliferation of T cells in the human peripheral blood monocytes obtained in the step 2; 4, using flow cytometry for determining T-cell subsets in the human peripheral blood monocytes obtained in the step 2; 5, using a CBA reagent box and a BD flow cytometer for detecting cell factors of the human peripheral blood monocytes obtained in the step 2.
Owner:WUHAN UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com